Travere Therapeutics TVTX announced that the FDA ... approval to its oral non-immunosuppressive drug Filspari (sparsentan) in IgA nephropathy (IgAN) indication, a rare progressive kidney disease.

The U.S. Food and Drug Administration has approved a new drug for ... causes of disability worldwide, the FDA reports. Individuals with this disease have a greater risk of dying young, and nearly ...

The FDA has approved Alnylam’s gene silencing drug ... As the kidney function worsens, oxalate can build up and damage other organs including the heart, bones and eyes. The disease is also ...

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to Travere ...

The FDA approved IntraBio Inc.'s Aqneursa (levacetylleucine) yesterday for the treatment of ultra rare neurodegenerative ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

The US Food and Drug Administration has approved Cobenfy ... and constipation. The FDA says people with known liver impairment or moderate to severe kidney impairment should not use the drug.

The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...

Basel, September 17, 2024 – Novartis today announced that the US Food and Drug ... disease-free survival (iDFS) benefit was consistently observed across all patient subgroups 3-6. “The FDA ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment ...

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...